Maria E. Riveiro

1 Place Paul Verlaine
Boulogne-billancourt, 92100, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Characterisation of anti-prostate cancer metabolites from a prefractionated South African medicinal plant library reveals a bioactive metabolite conversion.

Characterisation of anti-prostate cancer metabolites from a prefractionated South African medicinal plant library reveals a bioactive metabolite conversion.

Journal: Fitoterapia

Published: May 12, 2026

From Predicting Cancer Treatment Response to Identifying Novel Therapeutic Targets using Graph Neural Networks.

From Predicting Cancer Treatment Response to Identifying Novel Therapeutic Targets using Graph Neural Networks.

Journal: IEEE journal of biomedical and health informatics

Published: October 16, 2025

A first-in-class Wiskott-Aldrich syndrome protein activator with antitumor activity in hematologic cancers.

A first-in-class Wiskott-Aldrich syndrome protein activator with antitumor activity in hematologic cancers.

Journal: Haematologica

Published: December 31, 2022

Role of the Tyrosine Phosphatase SHP-2 in Mediating Adrenomedullin Proangiogenic Activity in Solid Tumors.

Role of the Tyrosine Phosphatase SHP-2 in Mediating Adrenomedullin Proangiogenic Activity in Solid Tumors.

Journal: Frontiers in oncology

Published: August 04, 2021

Development of potent dual PDK1/AurA kinase inhibitors for cancer therapy: Lead-optimization, structural insights, and ADME-Tox profile.

Development of potent dual PDK1/AurA kinase inhibitors for cancer therapy: Lead-optimization, structural insights, and ADME-Tox profile.

Journal: European journal of medicinal chemistry

Published: July 21, 2021

Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy.

Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy.

Journal: Frontiers in oncology

Published: July 30, 2020

Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models.

Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models.

Journal: Leukemia & lymphoma

Published: June 18, 2019

Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of Stem-like Tumor Cells in Human Prostate Cancer.

Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of Stem-like Tumor Cells in Human Prostate Cancer.

Journal: Cell metabolism

Published: June 11, 2018

BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance.

BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance.

Journal: ESMO open

Published: April 25, 2018

Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma.

Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma.

Journal: Haematologica

Published: February 20, 2018

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.

Journal: Oncotarget

Published: July 25, 2016

Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.

Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.

Journal: Oncotarget

Published: July 07, 2016

Showing 1-12 of 31

Last Updated: 09/26/2026